The bromo-and extra-terminal domain (BET) family of proteins are epigenetic reader proteins involved in transcription regulation and chromatin remodelling.
1,2 The family consists of BRD2, BRD3 and BRD4, which are ubiquitously expressed, and BRDT, which is expressed only in the testes. Each BET protein contains two bromodomain structural motifs, here designated as D1 and D2, which have been shown to bind acetylated lysines on histones H3 and H4, and existing data indicates that the biology of BET proteins is largely regulated through the first bromodomain.
3,4 The acetylated histone lysine residues bind into a hydrophobic pocket of the BET proteins making specific hydrogen bonding interactions with a conserved asparagine and tyrosine residue, the latter through a water molecule. 5 In the last six years a number of research teams have identified high affinity, small molecule ligands for this hydrophobic pocket that block binding to the cognate acetylated histones. [6] [7] [8] [9] [10] Such small molecule BET inhibitors, along with genetic deletion studies, have demonstrated that inhibition of the BET -histone interaction can result in profound disruption of transcriptional programs resulting in anticancer and anti-inflammatory activity, amongst others. For example, treatment of cancer cells dependent on the oncogene c-MYC with BET inhibitors, either in vitro or in vivo, can result in significant antiproliferative and cytotoxic effects. As a consequence of these and other data, at least ten BET inhibitors have now entered clinical trials for the treatment of a range of hematological cancers (incl. leukemia, lymphoma and myeloma), certain solid tumors (including glioblastoma multiforme and NUTmidline carcinoma) and atherosclerosis.
2,11
The first potent BET inhibitors described in the literature were the benzodiazepine IBET-762 (1) 12, 13 and the related thienodiazepine (S)-JQ-1 (2) (Chart 1).
14 Co-crystal structures of these compounds with BRD4(D1) revealed that the 1,2,4-triazole within these inhibitors acts as an acetyl-lysine mimic by interacting with Asn140 and a conserved water molecule in the KAc recognition pocket. Constellation Pharmaceuticals have reported isoxazole azepines (e.g. 3) 15 and benzotriazolo [4,3- 
16 that also inhibit BET bromodomains, while Knapp and coworkers reported that benzotriazepine 5 binds to BRD4. 17 Interestingly, based on structural similarities to IBET-762, a range of benzodiazepine drugs were retrospectively tested for inhibition of BRD4(D1). 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Of these, alprazolam (6) was found to be a weak inhibitor (K d = 2.5 µM) and X-ray crystallography confirmed the 1,2,4-triazole acts as an acetyl lysine mimetic. Other closely related analogues of alprazolam that were devoid of the 1,2,4-triazole motif were found to be inactive, 17 underscoring the importance of the acetyl lysine mimicking heterocycle for BET activity.
We have been interested in understanding the impact of the KAc mimicking pharmacophore on bromodomain inhibition. Based on previous studies 18 we designed and tested compounds based on a 5H-benzo [f] [1, 2, 3] triazolo [1,5-d] [1,4]diazepine nucleus. The 1,2,3-triazole motif was predicted to have appropriate hydrogen-bond accepting vector at N2 to interact with the conserved asparagine [Asn140 in BRD4(D1)] and molecular modeling indicated that a phenyl substituent at N7 of the diazepine ring would project into the WPF shelf, closely mapping over chlorophenyl (C6) of 3H-benzo-1,4-diazepines JQ-1 and IBET-762. We found that this is an excellent BET bromodomain-binding framework and, through subsequent structure-based optimization, developed a series of 1,2,3-triazolobenzodiazepines that display potent BET bromodomain inhibition and excellent cellular activity.
Initially, we prepared 1,2,3-triazole-containing benzodiazepine 7 via the route shown in Scheme 1. Starting from 1,2-diiodobenzene (8), Buchwald coupling with aniline afforded diarylaniline 9. The propyne was introduced at the remaining iodinated position using Sonogashira cross-coupling and the product (10) was acetylated with chloroacetyl chloride providing chloroacetamide 11. Based on a report by Majumdar et. al. and others, [19] [20] [21] we performed a one-pot S N 2/Hüigsen 1,3-dipolar cycloaddition reaction cascade to directly prepare the 1,2,3-triazolobenzodiazepine framework by heating 11 to 150 o C in the presence of sodium azide. While this strategy provided triazole 12 as expected, the un-optimized yield in this case was low (13%). Nevertheless, with the diazepinone in hand, selective deletion of the carbonyl oxygen with borane provided the desired 1,2,3-triazolobenzodiazepine 7. Using an optimized version of this general strategy, followed by additional late-stage cross-coupling reactions and other functional group interconversions, we synthesized a range of analogs shown in Table 1 (see electronic supporting information for full synthetic details).
Initially we assessed the BET inhibitory activity of 7 using AlphaScreen TM , a well-validated competition binding assay. Gratifyingly, 7 showed good activity in this assay against all bromodomains tested with the strongest activity against BRD4(D2) (IC 50 = 22 nM), but significantly weaker activity against BRD2(D1) (IC 50 = 264 nM) ( Figure 1 and Table 1 ). Control compound, JQ-1, gave BRD4(D2) IC 50 = 12 nM and BRD2(D1) IC 50 = 26 nM (Figure 1 ). We also tested the diazepinone (12) but this was essentially inactive (IC 50 greater than 10 µM, data not shown). The good ligand efficiency [0.51 kcal.mol -1 per non-hydrogen atom for BRD4(D2)] of 7 prompted us to expand this series and explore structure-activity relationships with the view to improve the overall BET activity. First we briefly examined modifications to the D-ring. Benzyl substitution at N7 (13) led to a reduction in activity by greater than 50-fold against all bromodomains tested, while addition of either meta or para substituents on the D-ring were tolerated in terms of overall activity with the 4-chlorophenyl-substituted analog 15 provided a modest improvement over the activity of parent compound 7 [about 2-fold improvement against BRD2(D1)], consistent with previous studies on BET inhibitors, and we therefore retained this modification in subsequent compounds. Next we investigated modifications to the A-ring. Crystal structures of both IBET-762 (pdb code 2YEK) or alprazolam (pdb code 3U5J) bound to BET bromodomains indicated that substitution at C9 (C8 in IBET-762 numbering) projected into the ZA channel and we extrapolated that our series of benzodiazepines would also accommodate functionalization at this position. A set of compounds was therefore designed to incorporate a substituent from the C9 vector. From the activity of the set of C9 analogs it was clear that sp 3 substitution provided no improvement in activity (compounds 16, 17 and 27), whereas heteroaryl substituents significantly improved activity, with pyrazole 18 and aminopyridine 20 giving IC 50 values as low as 7 and 6 nM respectively against BRD4(D2). Interestingly, tetrazole 22 showed the greatest activity across each bromodomain with IC 50 values ranging from 7 nM against BRD2(D2) to 2 nM against BRD4(D2). At this point we established the binding mode of the aminopyridylsubstituted compound (20) in BRD2(D2) by single crystal Xray analysis (Figure 2) . The structure confirmed that the 1,2,3-triazole motif acts as an acetyl-lysine mimetic, accepting a hydrogen bond from both Asn429 and the conserved water molecule coordinated to Tyr386, as expected. Additionally, the chlorophenyl ring lies within the WPF shelf and the aminopyridine ring extends through the ZA channel and towards solvent exposed space. The positioning of the aminopyridine towards solvent indicated that modifications to this position should be well tolerated. Based on these structural insights we reasoned that other sp 2 -hybridized moities, such as carbonyls, might also improve potency and allow for greater diversity of functionalization. Initially we compared carboxylic acids, esters and simple amides. In general, these derivatives showed good activity. Of the initial carbonyl series, primary amide 25 was significantly more potent (~3-fold) against all BET bromodomains tested compared with ester 23 and prompted us to explore the amide derivatives further. The benzyl amide series (compounds 29 to 33) were also exceptionally potent, particularly chiral benzyl amides 29, 30 and 31. Further, in the amide series the Sconfigured amides 29 and 30 displayed significant domain selectivity [BRD2(D2) vs BRD2(D1)] realtive to the Rconfigured analog 31. In light of the potent activity of the tetrazole, 22, we explored bioisosteric acylsulfonamides at the C9 position. These compounds, although somewhat less active than the tetrazole, also displayed low nanomolar activity against BRD4(D2) despite the significantly increased steric bulk, further attesting to the accomodation of sp 2 -modifications at C9. Lastly, we investigated substitutions to the benzodiazepine ring. Methyl substitution at C5 (Compounds 36, 37) improved activity against BRD4(D1) and the R-stereogenic configuration was preferred consistent with similar modification of previously reported benzodiazepine BET inhibitors. 16 From this chemical series we selected compounds 18 and 20 for further study because they displayed potent activity and were predicted to have good cell permeability (for example the tetrazole 22, while potent, is likely an efflux transporter substrate). 22 First, we assessed the bromodomain selectivity of 20 across a panel of 32 recombinant human bromodomains in a bromoMAX TM assay (see electronic supporting information for full data). In these assays, 20 showed excellent selectivity for the BET family bromodomains. We also assessed the binding kinetics of 20 against individual bromodomains using surface plasmon resonance (SPR). The dissociation-rate measured for compound 20 against BRD2 was approximately 3-fold slower for domain 2 than domain 1 (k d = 0.039 s -1 vs k d = 0.13 s -1 , respectively), whereas association rates were similar (k a = 2.90 x10 5 M -1 s -1 vs k a = 2.62 x10 5 M -1 s -1 , respectively) (see electronic supporting information for full data).
BET inhibition has been shown to have a remarkable effect on certain primary cancer cells and cell lines, which is thought to be a consequence of downregulation of oncogenes c-MYC, BCL-2 and others by displacement of BRD4 from hyperacetylated histone tails near their respective promoters and enhancers. 23, 24 To test the anti-leukemic effect of this chemical series we profiled 18 and 20 against a cancer cell panel (Table 2 ). Compound 20 potently inhibited proliferation of known BRD4-dependant leukemic line MLL-AF9, and showed significant inhibition of leukemic macrophage cell line MV4-11, (EC 50 = 140 nM), whereas B cell lymphoma lines DOHH2, SU-DHL-4 and Raji, and myeloma cell line RPMI-8226 were less sensitive (EC 50 > 500 nM). Consistent with BET-targeted anti-proliferative effects, BCR-Abl-driven cell line K562 was completely resistant to 20 (>1000 nM). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59Table 1 . Inhibition of BET bromodomains as determined by AlphaScreen TM assays. Numbers represent mean IC 50 in nanomolar (nM) of at least two independent experiments. A. D-ring modifications. B C9 sp3 functionalized derivatives. C C9 sp2-functionalized derivatives. D C9 carbonyl derivatives. E miscellaneous C9 derivatives. F C9 benzylamide derivatives. G Acylsulphonamides. H C5 Alkyl derivatives. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Osteosarcoma (OS) cells are also known to be sensitive to BET inhibition, but through a MYC-independent mechanism. 25 We were therefore interested to characterize the effect of 18 and 20 on primary mouse OS cells (fibroblastic 494H and osteoblastic 148I). Both compounds 18 and 20 inhibited proliferation of both primary OS cell types, serving to highlight the broad utility of 1,2,3-triazolobenzodiazepines derivatives in cancer studies. The cellular potency profile of 18 and 20 also closely correlated with positive control JQ-1.
We used RNA-seq to compare the effect of 20 and JQ-1 on global gene expression in THP-1 leukemia cells. These experiments revealed that the effect on gene expression between these two compounds is highly correlated for both up and down regulated genes ( Figure 3A) . In particular, BRD4-dependent oncogene c-MYC demonstrated robust downregulation on treatment with 20 ( Figure 3B ) whilst HEXIM1 levels were upregulated. 26 Similar effects on c-MYC and BCL-2 downregulation were observed for JQ-1, 18, 20 and non-diazepine BET inhibitor IBET-151 in MV4-11 cells (data not shown, see electronic supporting information for full data). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
